Sign in
TerminatedPhase 1

A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Israel, Netherlands, Spain, and Switzerland5 sites in 4 countriesChoose a country to see its sites
Status
Terminated
Phase
Phase 1
People taking part
24 people enrolled
Started
6 Oct 2023
Ended
13 Dec 2024
Type of study
Interventional
Treatments tested
  • 68Ga-FF58
  • 177Lu-FF58
Record updated
24 December 2025
Why it stopped
The decision was not based on any safety concerns

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Age >= 18 years old
  • Patients with locally advanced unresectable or metastatic PDAC, locally advanced unresectable or metastatic GEA, or recurrent GBM
  • To be treated with [177Lu]Lu-FF58, patients must have at least one measurable lesion that shows [68Ga]Ga-FF58 uptake on PET/CT or PET/MRI

Who cannot take part

  • Prior external beam radiation therapy (EBRT) to > 25% of the bone marrow
  • Non-GBM patients: Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids within 1 week before [177Lu]Lu-FF58 administration; Other protocol-defined inclusion/exclusion criteria may apply
  • Absolute neutrophil count (ANC) < 1.5 x 109/L, hemoglobin < 10 g/dL, or platelet count < 100 x 109/L
  • Creatinine clearance < 60 mL/min
  • Unmanageable bladder outflow obstruction or urinary incontinence

This trial has no sites in United States.

It has sites in 4 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of the study is to test the safety and dosing of [177Lu]Lu-FF58, a radioligand therapy for patients with advanced or metastatic tumors that express proteins known as integrins: alpha-v beta-3 integrin (αvβ3) and alpha-v beta-5 integrin (αvβ5). The study will also further characterize the radioligand imaging agent [68Ga]Ga-FF58 including its ability to identify tumor lesions and its safety profile.

The group in the trial

  • Arm 1Treatment being tested

    Patients will receive 68Ga-FF58 and only patients with tumor uptake of 68Ga-FF58 will receive 177Lu-FF58.

    Treatment: 68Ga-FF58 and 177Lu-FF58

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry and Preliminary Activity of [177Lu]Lu-FF58 in Patients With Selected Advanced Solid Tumors.
Record updated
24 December 2025